Hypermethylation and global remodelling of DNA methylation is associated with acquired cisplatin resistance in testicular germ cell tumours.
Cisplatin
DNA methylation
chemoresistance
testicular germ cell tumour
Journal
Epigenetics
ISSN: 1559-2308
Titre abrégé: Epigenetics
Pays: United States
ID NLM: 101265293
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
pubmed:
1
11
2020
medline:
13
1
2022
entrez:
31
10
2020
Statut:
ppublish
Résumé
Testicular germ cell tumours (TGCTs) respond well to cisplatin-based therapy. However, cisplatin resistance and poor outcomes do occur. It has been suggested that a shift towards DNA hypermethylation mediates cisplatin resistance in TGCT cells, although there is little direct evidence to support this claim. Here we utilized a series of isogenic cisplatin-resistant cell models and observed a strong association between cisplatin resistance in TGCT cells and a net increase in global CpG and non-CpG DNA methylation spanning regulatory, intergenic, genic and repeat elements. Hypermethylated loci were significantly enriched for repressive DNA segments, CTCF and RAD21 sites and lamina associated domains, suggesting that global nuclear reorganization of chromatin structure occurred in resistant cells. Hypomethylated CpG loci were significantly enriched for EZH2 and SUZ12 binding and H3K27me3 sites. Integrative transcriptome and methylome analyses showed a strong negative correlation between gene promoter and CpG island methylation and gene expression in resistant cells and a weaker positive correlation between gene body methylation and gene expression. A bidirectional shift between gene promoter and gene body DNA methylation occurred within multiple genes that was associated with upregulation of polycomb targets and downregulation of tumour suppressor genes. These data support the hypothesis that global remodelling of DNA methylation is a key factor in mediating cisplatin hypersensitivity and chemoresistance of TGCTs and furthers the rationale for hypomethylation therapy for refractory TGCT patients.
Identifiants
pubmed: 33126827
doi: 10.1080/15592294.2020.1834926
pmc: PMC8510620
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1071-1084Subventions
Organisme : NCI NIH HHS
ID : R01 CA211875
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA223709
Pays : United States
Organisme : NIH HHS
ID : T35 OD011145
Pays : United States
Références
Oncotarget. 2017 Jan 10;8(2):2949-2959
pubmed: 27936464
Int J Mol Sci. 2019 Jan 10;20(2):
pubmed: 30634670
Front Pharmacol. 2018 Apr 13;9:366
pubmed: 29706891
Urol Clin North Am. 2019 Aug;46(3):377-388
pubmed: 31277732
PLoS One. 2014 Jun 02;9(6):e98330
pubmed: 24887064
Nat Rev Genet. 2016 Sep 15;17(10):630-41
pubmed: 27629931
J Cancer. 2019 Jan 29;10(4):893-902
pubmed: 30854095
Int J Mol Sci. 2018 Dec 21;20(1):
pubmed: 30577584
Semin Cancer Biol. 2014 Dec;29:59-74
pubmed: 25066859
Cell Rep. 2018 Jun 12;23(11):3392-3406
pubmed: 29898407
Cancer Res. 2009 Dec 15;69(24):9360-6
pubmed: 19951990
Biology (Basel). 2014 Nov 11;3(4):739-51
pubmed: 25393317
J Pathol. 2010 Aug;221(4):433-42
pubmed: 20593487
Curr Opin Urol. 2020 Mar;30(2):264-270
pubmed: 31905176
Genome Res. 2016 Nov;26(11):1490-1504
pubmed: 27803193
Cancer Inform. 2019 Feb 11;18:1176935119828776
pubmed: 30792573
Nat Commun. 2020 May 4;11(1):2189
pubmed: 32366847
Curr Oncol Rep. 2017 Feb;19(2):8
pubmed: 28220447
Br J Cancer. 2014 Apr 15;110(8):2131-8
pubmed: 24603304
Bioinformatics. 2016 Feb 15;32(4):587-9
pubmed: 26508757
Cells. 2019 Mar 21;8(3):
pubmed: 30901978
Cancer Treat Rev. 2020 Aug;88:102054
pubmed: 32593915
Cancer Drug Resist. 2019;2(3):580-594
pubmed: 31538140
Nucleic Acids Res. 2016 Jan 8;44(1):75-94
pubmed: 26635396
Mol Cancer. 2004 May 18;3:16
pubmed: 15149548
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Rev Urol. 2019 Apr;16(4):245-259
pubmed: 30765888
Gene. 2020 Oct 20;758:144966
pubmed: 32687945
PLoS One. 2012;7(12):e53003
pubmed: 23300844
Cancer. 2012 Feb 15;118(4):981-6
pubmed: 21792865
Genome Biol. 2014 Dec 03;15(12):503
pubmed: 25599564
Curr Oncol Rep. 2018 Sep 26;20(11):88
pubmed: 30259297
Cell Mol Life Sci. 2019 May;76(9):1713-1727
pubmed: 30671589
Front Genet. 2017 Jun 07;8:76
pubmed: 28638402
Cancers (Basel). 2019 Jun 08;11(6):
pubmed: 31181810
Nucleic Acids Res. 2017 Sep 6;45(15):8697-8711
pubmed: 28911103
Bioinformatics. 2017 Feb 15;33(4):558-560
pubmed: 28035024
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Sci Rep. 2017 Sep 12;7(1):11295
pubmed: 28900200
Cancer Genet. 2020 Feb;241:42-50
pubmed: 31653608
Cancers (Basel). 2020 Jun 17;12(6):
pubmed: 32560427
Trends Cancer. 2018 Aug;4(8):583-597
pubmed: 30064665
Epigenetics. 2013 Feb;8(2):203-9
pubmed: 23314698
Urol Clin North Am. 2015 Aug;42(3):359-68
pubmed: 26216823
J Natl Compr Canc Netw. 2019 Dec;17(12):1557-1568
pubmed: 31805527
Oncotarget. 2016 Aug 10;8(31):50608-50617
pubmed: 28881587
Nucleic Acids Res. 2017 Feb 28;45(4):e22
pubmed: 27924034
Clin Adv Hematol Oncol. 2017 May;15(5):386-396
pubmed: 28591093